Morphic to Present at the 42nd Annual J.P. Morgan Healthcare Conference
03 Enero 2024 - 3:05PM
Morphic Therapeutic (Nasdaq: MORF), a biotechnology company
developing a new generation of oral integrin therapies for the
treatment of serious chronic diseases, today announced that Praveen
Tipirneni, M.D., Chief Executive Officer of Morphic, has returned
in full capacity from a previously announced temporary medical
leave of absence and will present at the 42nd Annual J.P.
Morgan Healthcare Conference on Wednesday, January 10, 2024 at 3:45
PM PT/6:45 PM ET. A live webcast of the presentation will be
available on the Investor section of Morphic’s website
at www.morphictx.com. An archived replay will be available on
the company’s website following the conference.
About Morphic
TherapeuticMorphic Therapeutic is a biopharmaceutical
company developing a portfolio of oral integrin therapies for the
treatment of serious chronic diseases, including autoimmune,
cardiovascular, and metabolic diseases, fibrosis, and cancer.
Morphic is also advancing its pipeline and discovery activities in
collaboration with Schrödinger using its proprietary MInT
technology platform which leverages the Company’s unique
understanding of integrin structure and biology. For more
information, visit www.morphictx.com.
ContactsMorphic
TherapeuticChris Erdmanchris.erdman@morphictx.com617.686.1718
Morphic (NASDAQ:MORF)
Gráfica de Acción Histórica
De Ago 2024 a Sep 2024
Morphic (NASDAQ:MORF)
Gráfica de Acción Histórica
De Sep 2023 a Sep 2024